Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,138,804
-
Number of holders
-
0
-
Total 13F shares, excl. options
-
0
-
Shares change
-
-2,263,871
-
Total reported value, excl. options
-
$0
-
Value change
-
-$605,057
-
Number of sells
-
-21
Significant Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q4 2022
23 filings reported holding QLGN - QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share as of Q4 2022.
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) has 0 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 0 shares
of 6,138,804 outstanding shares and own 0% of the company stock.
Largest 10 shareholders include NORTHERN TRUST CORP (0 shares), PRICE T ROWE ASSOCIATES INC /MD/ (0 shares), GROUP ONE TRADING, L.P. (0 shares), RENAISSANCE TECHNOLOGIES LLC (0 shares), VANGUARD GROUP INC (0 shares), US BANCORP \DE\ (0 shares), FRANKLIN RESOURCES INC (0 shares), COMMONWEALTH EQUITY SERVICES, LLC (0 shares), BANK OF AMERICA CORP /DE/ (0 shares), and WEDBUSH SECURITIES INC (0 shares).
This table shows the top 0 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.